No abstract available.
Dermatitis, Perioral ; Ivermectin

Eyelid Diseases ; diagnosis ; immunology ; pathology ; Facial Dermatoses ; diagnosis ; immunology ; pathology ; HIV Infections ; complications ; immunology ; Humans ; Immunocompromised Host ; Male ; Middle Aged ; Molluscum Contagiosum ; complications ; diagnosis ; immunology ; pathology

Facial Dermatoses ; diagnosis ; pathology ; Humans ; Male ; Pyoderma Gangrenosum ; diagnosis ; pathology ; Sweet Syndrome ; diagnosis ; pathology ; Young Adult

No abstract available.
Carcinoma, Basal Cell ; Facial Dermatoses* ; Keratosis, Actinic ; Skin*

No abstract available.
Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood/*complications/diagnosis/drug therapy/physiopathology ; Biological Markers/blood ; Drug Therapy, Combination ; Facial Dermatoses/complications/diagnosis ; Female ; Hand Joints/physiopathology/radiography ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammation Mediators/blood ; Knee Joint/physiopathology/radiography ; Lupus Erythematosus, Systemic/blood/*complications/diagnosis/drug therapy ; Middle Aged ; Syndrome ; Treatment Outcome

Childhood granulomatous periorificial dermatitis (CGPD) is a distinctive granulomatous form of perioral dermatitis. It is characterized by papular eruptions located around the mouth, nose, and eyes, and rarely present eczematous patches or plaques. Histopathologic examination shows upper dermal and perifollicular granulomatous infiltrates. Herein, we report two cases of CGPD that were presented with erythematous plaques. One patient was treated with 0.03% topical tacrolimus and the other patient with oral metronidazole. The patients responded well to their respective therapies, showing resolution of the lesions.
Dermatitis* ; Dermatitis, Perioral ; Humans ; Metronidazole ; Mouth ; Nose ; Tacrolimus

Childhood granulomatous periorificial dermatitis (CGPD) is a distinctive granulomatous form of perioral dermatitis. It is characterized by papular eruptions located around the mouth, nose, and eyes, and rarely present eczematous patches or plaques. Histopathologic examination shows upper dermal and perifollicular granulomatous infiltrates. Herein, we report two cases of CGPD that were presented with erythematous plaques. One patient was treated with 0.03% topical tacrolimus and the other patient with oral metronidazole. The patients responded well to their respective therapies, showing resolution of the lesions.
Dermatitis* ; Dermatitis, Perioral ; Humans ; Metronidazole ; Mouth ; Nose ; Tacrolimus

OBJECTIVETo observe the clinical effect of micro-plasma radio frequency treatment of facial post-burn hyperpigmentation.

METHODSFrom June 2012 to August 2013, a total of 25 cases with facial post-burn hyperpigmentation were treated with micro-plasma treatment for 3-5 times. The roller tip was used with setting of 60-90 watts and 3-4 passes were performed in different directions. Treatments were repeated at an interval of 8 weeks.

RESULTSAll patients tolerated the pain. After treatment, the facial hyperpigmentation improved. Complete recovery was achieved in 4 cases; significant improvement in 11 cases; moderate in 7 cases and no effect in 3 cases. No hyperpigmentation, depigmentation and scar formation was observed.

CONCLUSIONMicro-plasma radio frequency treatment is an ideal treatment for post-burn hyperpigmentation with lower side effect.

Aged ; Burns ; complications ; Cicatrix ; Facial Dermatoses ; etiology ; therapy ; Facial Injuries ; complications ; Humans ; Hyperpigmentation ; etiology ; therapy ; Pulsed Radiofrequency Treatment ; instrumentation ; methods

BACKGROUND: Perioral dermatitis (POD) is a common inflammatory skin disease without standard therapy. OBJECTIVE: We sought to evaluate the clinical value of a soothing fluid for the treatment of POD. METHODS: We included 51 patients with POD in this 8-week clinical trial. The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) study had an open-label design and involved twice-daily application of Toleriane Fluide, a soothing cosmetic fluid. Clinical assessment of POD was performed with a predefined questionnaire including the POD severity index (PODSI). Control visits were made after 4 and 8 weeks of treatment. RESULTS: The results were compared with those of a historical control group treated with a vehicle cream. Patients treated with the soothing fluid showed a continuous and significant improvement of the PODSI over time. The improvement of PODSI observed with the soothing fluid was better, but not significantly better, than that observed in the historical controls. In addition, the subjective complaints of patients such as disease burden, itching, distension of the skin, and appearance improved during treatment. CONCLUSION: A soothing fluid could be a clinically useful treatment option for POD.
Dermatitis, Perioral* ; Humans ; Pruritus ; Skin ; Skin Diseases ; Surveys and Questionnaires

BACKGROUND: Periocular dermatitis (PD) is a common condition and can be classified as either allergic or non-allergic. Because the periocular region is one of the most sensitive areas of the skin, contact with any environmental or therapeutic allergen may give rise to dermatitis. OBJECTIVE: The aim of this study was to investigate the clinical usefulness of patch testing to determine sensitivity to contact allergens in PD patients. METHODS: Patch testing was conducted in 29 PD patients using the T.R.U.E. test(R) at Pusan National University Hospital. We examined the results of patch testing, the probable cause of PD, and the history of use of ophthalmic medication. RESULTS: Contact hypersensitivity was detected using the T.R.U.E. test(R) in 62.1% (18/29) of the patients, and contact hypersensitivity to specific ophthalmic medications was observed in 33.3% (3/9) of the patients with a history of using ophthalmic medication. CONCLUSION: We suggest that patch testing can be utilized to elucidate the relevant contact allergen in patients with PD. Patch testing with specific ophthalmic medications is valuable to determine allergic reactions in patients who have used ophthalmic medications.
Allergens* ; Busan ; Dermatitis ; Dermatitis, Contact ; Dermatitis, Perioral* ; Humans ; Hypersensitivity ; Patch Tests* ; Skin